CN112111010B - 一种特异性抗噻虫啉抗体的可变区序列及其重组完整抗体 - Google Patents
一种特异性抗噻虫啉抗体的可变区序列及其重组完整抗体 Download PDFInfo
- Publication number
- CN112111010B CN112111010B CN202010736700.2A CN202010736700A CN112111010B CN 112111010 B CN112111010 B CN 112111010B CN 202010736700 A CN202010736700 A CN 202010736700A CN 112111010 B CN112111010 B CN 112111010B
- Authority
- CN
- China
- Prior art keywords
- antibody
- thiacloprid
- variable region
- heavy chain
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000005940 Thiacloprid Substances 0.000 title claims abstract description 57
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
- 239000013613 expression plasmid Substances 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- HOKKPVIRMVDYPB-UVTDQMKNSA-N (Z)-thiacloprid Chemical group C1=NC(Cl)=CC=C1CN1C(=N/C#N)/SCC1 HOKKPVIRMVDYPB-UVTDQMKNSA-N 0.000 abstract description 23
- 241001529936 Murinae Species 0.000 abstract description 8
- 239000013612 plasmid Substances 0.000 abstract description 8
- 238000003018 immunoassay Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 239000013604 expression vector Substances 0.000 abstract description 5
- 210000004962 mammalian cell Anatomy 0.000 abstract description 5
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 238000001514 detection method Methods 0.000 description 19
- 238000000034 method Methods 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 7
- 239000000575 pesticide Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 239000002917 insecticide Substances 0.000 description 4
- 239000000447 pesticide residue Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- QJXHMYMRGDOHRU-NHCYSSNCSA-N Leu-Ile-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O QJXHMYMRGDOHRU-NHCYSSNCSA-N 0.000 description 2
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- -1 chloronicotinyl Chemical group 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000002352 surface water Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- WCXDHFDTOYPNIE-RIYZIHGNSA-N (E)-acetamiprid Chemical compound N#C/N=C(\C)N(C)CC1=CC=C(Cl)N=C1 WCXDHFDTOYPNIE-RIYZIHGNSA-N 0.000 description 1
- VXLYOURCUVQYLN-UHFFFAOYSA-N 2-chloro-5-methylpyridine Chemical compound CC1=CC=C(Cl)N=C1 VXLYOURCUVQYLN-UHFFFAOYSA-N 0.000 description 1
- 239000005875 Acetamiprid Substances 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- OMDNCNKNEGFOMM-BQBZGAKWSA-N Ala-Met-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O OMDNCNKNEGFOMM-BQBZGAKWSA-N 0.000 description 1
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 1
- NTWOPSIUJBMNRI-KKUMJFAQSA-N Asn-Lys-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTWOPSIUJBMNRI-KKUMJFAQSA-N 0.000 description 1
- YQPSDMUGFKJZHR-QRTARXTBSA-N Asn-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)N YQPSDMUGFKJZHR-QRTARXTBSA-N 0.000 description 1
- JPPLRQVZMZFOSX-UWJYBYFXSA-N Asn-Tyr-Ala Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=C(O)C=C1 JPPLRQVZMZFOSX-UWJYBYFXSA-N 0.000 description 1
- VAWNQIGQPUOPQW-ACZMJKKPSA-N Asp-Glu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VAWNQIGQPUOPQW-ACZMJKKPSA-N 0.000 description 1
- LIVXPXUVXFRWNY-CIUDSAMLSA-N Asp-Lys-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O LIVXPXUVXFRWNY-CIUDSAMLSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- AMRLSQGGERHDHJ-FXQIFTODSA-N Cys-Ala-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMRLSQGGERHDHJ-FXQIFTODSA-N 0.000 description 1
- NOCCABSVTRONIN-CIUDSAMLSA-N Cys-Ala-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CS)N NOCCABSVTRONIN-CIUDSAMLSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- HHWQMFIGMMOVFK-WDSKDSINSA-N Gln-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O HHWQMFIGMMOVFK-WDSKDSINSA-N 0.000 description 1
- MAGNEQBFSBREJL-DCAQKATOSA-N Gln-Glu-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N MAGNEQBFSBREJL-DCAQKATOSA-N 0.000 description 1
- VNTGPISAOMAXRK-CIUDSAMLSA-N Gln-Pro-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O VNTGPISAOMAXRK-CIUDSAMLSA-N 0.000 description 1
- DUGYCMAIAKAQPB-GLLZPBPUSA-N Gln-Thr-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DUGYCMAIAKAQPB-GLLZPBPUSA-N 0.000 description 1
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 1
- JWNZHMSRZXXGTM-XKBZYTNZSA-N Glu-Ser-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWNZHMSRZXXGTM-XKBZYTNZSA-N 0.000 description 1
- YHYDTTUSJXGTQK-UWVGGRQHSA-N Gly-Met-Leu Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(C)C)C(O)=O YHYDTTUSJXGTQK-UWVGGRQHSA-N 0.000 description 1
- GGAPHLIUUTVYMX-QWRGUYRKSA-N Gly-Phe-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)C[NH3+])CC1=CC=CC=C1 GGAPHLIUUTVYMX-QWRGUYRKSA-N 0.000 description 1
- FKESCSGWBPUTPN-FOHZUACHSA-N Gly-Thr-Asn Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O FKESCSGWBPUTPN-FOHZUACHSA-N 0.000 description 1
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 1
- FFALDIDGPLUDKV-ZDLURKLDSA-N Gly-Thr-Ser Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O FFALDIDGPLUDKV-ZDLURKLDSA-N 0.000 description 1
- TVQGUFGDVODUIF-LSJOCFKGSA-N His-Arg-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CN=CN1)N TVQGUFGDVODUIF-LSJOCFKGSA-N 0.000 description 1
- 101001134437 Homo sapiens Immunoglobulin lambda joining 1 Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- ASCFJMSGKUIRDU-ZPFDUUQYSA-N Ile-Arg-Gln Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O ASCFJMSGKUIRDU-ZPFDUUQYSA-N 0.000 description 1
- YBKKLDBBPFIXBQ-MBLNEYKQSA-N Ile-Thr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)O)N YBKKLDBBPFIXBQ-MBLNEYKQSA-N 0.000 description 1
- DGTOKVBDZXJHNZ-WZLNRYEVSA-N Ile-Thr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N DGTOKVBDZXJHNZ-WZLNRYEVSA-N 0.000 description 1
- 102100034172 Immunoglobulin lambda joining 1 Human genes 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- HASRFYOMVPJRPU-SRVKXCTJSA-N Leu-Arg-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HASRFYOMVPJRPU-SRVKXCTJSA-N 0.000 description 1
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
- YWKNKRAKOCLOLH-OEAJRASXSA-N Leu-Phe-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YWKNKRAKOCLOLH-OEAJRASXSA-N 0.000 description 1
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- HQBOMRTVKVKFMN-WDSOQIARSA-N Leu-Trp-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(O)=O HQBOMRTVKVKFMN-WDSOQIARSA-N 0.000 description 1
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 1
- DBMLDOWSVHMQQN-XGEHTFHBSA-N Met-Ser-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DBMLDOWSVHMQQN-XGEHTFHBSA-N 0.000 description 1
- ATBJCCFCJXCNGZ-UFYCRDLUSA-N Met-Tyr-Phe Chemical compound C([C@H](NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 ATBJCCFCJXCNGZ-UFYCRDLUSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 1
- VXCHGLYSIOOZIS-GUBZILKMSA-N Pro-Ala-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 VXCHGLYSIOOZIS-GUBZILKMSA-N 0.000 description 1
- KIGGUSRFHJCIEJ-DCAQKATOSA-N Pro-Asp-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O KIGGUSRFHJCIEJ-DCAQKATOSA-N 0.000 description 1
- HAEGAELAYWSUNC-WPRPVWTQSA-N Pro-Gly-Val Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAEGAELAYWSUNC-WPRPVWTQSA-N 0.000 description 1
- NTXFLJULRHQMDC-GUBZILKMSA-N Pro-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@@H]1CCCN1 NTXFLJULRHQMDC-GUBZILKMSA-N 0.000 description 1
- BUEIYHBJHCDAMI-UFYCRDLUSA-N Pro-Phe-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BUEIYHBJHCDAMI-UFYCRDLUSA-N 0.000 description 1
- BGWKULMLUIUPKY-BQBZGAKWSA-N Pro-Ser-Gly Chemical compound OC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BGWKULMLUIUPKY-BQBZGAKWSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- LWMQRHDTXHQQOV-MXAVVETBSA-N Ser-Ile-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LWMQRHDTXHQQOV-MXAVVETBSA-N 0.000 description 1
- MQUZANJDFOQOBX-SRVKXCTJSA-N Ser-Phe-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O MQUZANJDFOQOBX-SRVKXCTJSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 1
- IXEGQBJZDIRRIV-QEJZJMRPSA-N Trp-Asn-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IXEGQBJZDIRRIV-QEJZJMRPSA-N 0.000 description 1
- CXPJPTFWKXNDKV-NUTKFTJISA-N Trp-Leu-Ala Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 CXPJPTFWKXNDKV-NUTKFTJISA-N 0.000 description 1
- ACGIVBXINJFALS-HKUYNNGSSA-N Trp-Phe-Gly Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N ACGIVBXINJFALS-HKUYNNGSSA-N 0.000 description 1
- VTFWAGGJDRSQFG-MELADBBJSA-N Tyr-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O VTFWAGGJDRSQFG-MELADBBJSA-N 0.000 description 1
- NUQZCPSZHGIYTA-HKUYNNGSSA-N Tyr-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NUQZCPSZHGIYTA-HKUYNNGSSA-N 0.000 description 1
- JVYIGCARISMLMV-HOCLYGCPSA-N Val-Gly-Trp Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N JVYIGCARISMLMV-HOCLYGCPSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- UQMPYVLTQCGRSK-IFFSRLJSSA-N Val-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N)O UQMPYVLTQCGRSK-IFFSRLJSSA-N 0.000 description 1
- JAIZPWVHPQRYOU-ZJDVBMNYSA-N Val-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O JAIZPWVHPQRYOU-ZJDVBMNYSA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 231100000507 endocrine disrupting Toxicity 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 108010083476 phenylalanyltryptophan Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 231100000175 potential carcinogenicity Toxicity 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种特异性抗噻虫啉抗体的可变区序列,重链可变区编码基因的氨基酸序列为SEQ ID NO:2所示。本发明还公开了一种抗噻虫啉重组完整抗体,包括重链恒定区、重链可变区、轻链恒定区和轻链可变区,重链可变区编码基因的氨基酸序列为如SEQ ID NO:2所示。本发明又公开了一种抗体表达质粒。将本发明得到的序列基因分别连接到包含了重链恒定区基因和轻链恒定区基因的表达载体,采用双质粒系统的哺乳动物细胞表达获得了重组完整抗体,保证了鼠源亲本抗体的识别活性,并使得抗噻虫啉抗体可大批量稳定生产,为噻虫啉残留检测的各种免疫分析方法提供了可靠的核心试剂。
Description
技术领域
本发明属于基因工程技术领域,尤其是涉及一种特异性抗噻虫啉抗体的可变区序列及其重组完整抗体的制备。
背景技术
噻虫啉(3-(6-氯-3-甲基吡啶)-1,3-噻唑烷-2-亚氰胺)是一种具有噻唑环的新型氯代烟碱类杀虫剂,因其结构独特,性能与传统烟碱类杀虫剂相比更为优异,而被广泛应用于防治刺吸式口器和咀嚼式口器害虫对农作物的危害。噻虫啉有较强的内吸和渗透作用,因此会分布在作物各个部位,且因其具有水溶性强和半衰期长等特点,很容易通过降雨和灌溉等途径进入到地表水和土壤中。研究表明,地表水、沉积物和土壤中存在着较高水平的噻虫啉残留,这些农药残留对蜜蜂等传粉动物、水生和土壤无脊椎动物造成了巨大威胁。还有研究认为,噻虫啉对人类具有潜在致癌性及可能的生殖毒性与内分泌干扰效应,因此2020年欧盟开始实施对噻虫啉的禁用令。为防止消费者和有益生物受到噻虫啉残留的危害,对环境和农产品中噻虫啉残留的及时监测具有重要的意义。
目前,针对噻虫啉残留的检测方法主要有基于仪器的检测方法和基于免疫分析的检测方法。仪器分析方法有HPLC、GC和MS等,这些仪器分析方法均具有很高精密度、准确度和灵敏度,能够满足噻虫啉的精准定性定量的检测要求,但仪器分析方法需要昂贵的分析仪器、专业的实验人员和复杂的样品前处理程序,因此很难实现大规模的现场快速分析,而免疫分析快速检测方法能满足农药残留现场检测以及大批量样本筛查的需求。
目前,已有抗噻虫啉单抗及其免疫快速检测方法的少量公开报道,例如Yin等人报道的基于噻虫啉抗体和抗原模拟表位多肽建立的ELISA方法对噻虫啉的检测灵敏度(IC50)和最低检测限(IC10)分别是26.3和1.4μg/L(Yin,W.;Hua,X.;Liu,X.;Shi,H.;Gee,S.J.;Wang,M.;Hammock,B.D.,Anal.Biochem.,2015,481,27–32.)。Ding等人报道的基于传统单抗建立的ELISA方法对噻虫啉的IC50和IC10分是2.31ng/mL和0.44ng/mL(Ding,Y.;Chen,H.;Yang,Q.;Feng,L.;Hua,X.;Wang,M.,RSC Adv.,2019,9,36825–36830.)。
农药免疫分析快速检测技术是基于农药抗原和抗体的特异性结合而实现的,故抗体的制备是农药免疫快速检测的核心关键。传统的抗体有多克隆抗体和单克隆抗体,均是通过免疫动物而制备的,且后者因只有一个抗原识别表位特异性强而被广泛应用于农药免疫分析快速检测。依赖杂交瘤细胞制备单克隆抗体这一技术生产成本高、耗时,且需要杂交瘤细胞的长期低温保存和定期驯化,但在这些过程中杂交瘤细胞会因保存条件不当,有效基因丢失或突变而无法产生有效的抗体。随着基因工程技术的发展,序列明确的重组抗体逐渐变成研究热点,包括单链抗体、Fab抗体、重组完整抗体等。在众多重组抗体表达系统中,哺乳动物细胞表达系统能够指导重组抗体的正确折叠,提供准确的多种翻译后的加工和修饰功能,因此可以稳定产生与亲本抗体活性一致的重组抗体,不仅证实了亲本抗体可变区序列的准确性,还可以解决常规抗体制备面临的许多问题,如传统抗体的批次间差异、细胞株传代保存过程中容易丢失有效基因而导致细胞株无法产生有效抗体。只要获得正确的抗体序列基因,就可以在体外大量制备多种形式的重组抗体(包括全长IgG完整抗体、单链抗体scfv、抗原识别片段Fab等),而无需牺牲小鼠来制备腹水抗体,操作简便,制备周期短,有利于大规模产生抗体,并有助于灵敏、可靠的农药残留快速检测技术的发展和应用。
发明内容
为了克服现有技术的不足,本发明提供一种灵敏度高、特异性强的抗噻虫啉重组完整抗体的制备方法和稳定生产,以及该抗体的应用。
本发明解决其技术问题所采用的技术方案是:一种特异性抗噻虫啉抗体的可变区序列,重链可变区编码基因的氨基酸序列为SEQ ID NO:2所示。
作为优选,重链可变区编码基因的核苷酸序列如SEQ ID NO:1所示。
作为优选,轻链可变区编码基因的氨基酸序列为SEQ ID NO:4所示。
作为优选,轻链可变区编码基因的核苷酸序列如SEQ ID NO:3所示。
本发明还公开了一种抗噻虫啉重组完整抗体,包括重链恒定区、重链可变区、轻链恒定区和轻链可变区,所述重链可变区编码基因的氨基酸序列为如SEQ ID NO:2所示。
作为优选,所述重链可变区编码基因的核苷酸序列为如SEQ ID NO:1所示。
作为优选,所述轻链可变区编码基因的氨基酸序列如SEQ ID NO:4所示。
作为优选,所述轻链可变区编码基因的核苷酸序列如SEQ ID NO:3所示。
本发明又公开了一种抗体表达质粒,含有上述任一项所述的重链可变区和小鼠重链IgG1恒定区的核苷酸序列,可以表达抗噻虫啉重组完整抗体的重链蛋白;或者,含有如权利要求3-4中任一项所述的轻链可变区和小鼠轻链Lambda恒定区的核苷酸序列,可以表达抗噻虫啉重组完整抗体的轻链蛋白。
本发明将一株能稳定分泌抗噻虫啉高特异、高灵敏单抗的杂交瘤细胞株的重链和轻链可变区基因成功扩增出来、测序和合成,采用同源重组技术分别构建了重链和轻链表达载体,并共转染至哺乳动物细胞HEK293F中,最终获得抗噻虫啉的重组完整抗体。经ELISA技术验证,该重组完整抗体与传统的抗噻虫啉小鼠腹水单抗相比,有一致的高灵敏度和高选择性,可以代替腹水单抗,应用于噻虫啉农药残留检测。
与现有技术相比,本发明具有以下优点:本发明公开的抗噻虫啉重组完整抗体的重链可变区、轻链可变区序列来源于经多次免疫小鼠、细胞融合及筛选得到的一株高特异性的抗噻虫啉的单克隆细胞株。将此序列基因分别连接到包含了重链恒定区基因和轻链恒定区基因的表达载体,采用双质粒系统的哺乳动物细胞表达获得了重组完整抗体,保证了鼠源亲本抗体的识别活性,并使得抗噻虫啉抗体可大批量稳定生产,为噻虫啉残留检测的各种免疫分析方法提供了可靠的核心试剂。
附图说明
图1为本发明以反转录获得的cDNA为模板,噻虫啉抗体重链可变区基因、轻链可变区基因PCR扩增琼脂糖凝胶电泳结果。
图2为本发明SDS-PAGE验证完整抗体在哺乳动物细胞HEK293F中的表达。
图3为本发明抗噻虫啉重组完整抗体和小鼠单克隆抗体对噻虫啉的ELISA竞争曲线(浓度从低到高依次为0.01,0.05,0.20,0.78,3.13,12.50,50μg/L)。
具体实施方式
为了使本技术领域的人员更好地理解本发明方案,下面将结合本发明实施例中的附图,对发明实施例中的技术方案进行清楚、完整的描述,显然,所描述的实施例仅仅是本发明的一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都应当属于本发明保护的范围,如无特殊说明,实施例中的实验方法均为常规方法。
本发明涉及的抗噻虫啉重组完整抗体包括重链恒定区、重链可变区、轻链恒定区和轻链可变区,其重链恒定区序列为小鼠IgG1的重链恒定区序列,该抗体的轻链恒定区序列为小鼠λ抗体轻链恒定区序列。
小鼠抗噻虫啉重组完整抗体的制备
1)抗噻虫啉单克隆抗体可变区基因扩增
经小鼠免疫、细胞融合和杂交瘤细胞筛选,制备了一株能分泌高特异性的抗噻虫啉抗体的杂交瘤细胞株C4C4,亚型IgG1/Lambda,采用Trizol法提取杂交瘤细胞的总RNA,经琼脂凝胶电泳鉴定RNA完整性较好可满足本实验的要求。以RNA为模板,采用Random 6mers和Oligo dT Primer混合的RT Primer Mix反转录合成cDNA。使用具有亚型特异性的引物进行单抗可变区PCR扩增,其中上游引物位于可变区前的信号肽部位,下游引物位于可变区之后的恒定区。
PCR扩增的程序为:
PCR扩增产物琼脂糖凝胶电泳结果参见图1,扩增出含有VH和VL基因片段的条带。用凝胶提取试剂盒纯化,将纯化后的产物克隆至PMD 19-T(氨苄抗性)载体并转化大肠杆菌TOP10感受态细胞后挑选10个单克隆菌落送测序,序列经NCBI数据库Blast比对后,鉴定出序列完整、亚型相符和正确表达框的VH和VL基因。
抗噻虫啉单克隆抗体C4C4重链可变区序列为:
CAGGTTACTCTGAGAGAGTCTGGCCCTGGGATGTTGCAGCCCTCCCAGACTCTCAGTCTGACCTGTTCTTTCTCTGGATTTTCAATGAGCACTTTTGCTATGGGTGTAGGCTGGATTCGTCAGCCTTCAGGGAAGGGACTGGAGTGGCTGGCAAGTATTTTTTGGAATGAGAATAAATATTATAATCCAGCCCTGATGAGCCGGCTCACAATCTCCAGGGATACCTCCAAAAACCTGGTTTTCCTCACGGTCGCCAGTGTGGACACTGCAGATACTGGCACATACTTCTGCGCTCGGATAACTTACCCCTTCTTTCCTATGGATTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA(SEQ ID NO:1)
功能性重链可变区全长为360个碱基,结构域从第1位碱基开始,编码120个氨基酸,该有功能的重链V-GENE与鼠源IGHV8-8*01F一致性为89.69%,J-GENE与鼠源IGHJ4*01F一致性为88.68%。
以IMGT法定义结构域,具体结构域划分为:
结构域 | FR1 | CDR1 | FR2 | CDR2 | FR3 | CDR3 | FR4 |
碱基序列 | 1-75 | 76-105 | 106-156 | 157-177 | 178-291 | 292-327 | 328-360 |
抗噻虫啉单克隆抗体C4C4重链可变区氨基酸序列
QVTLRESGPGMLQPSQTLSLTCSFSGFSMSTFAMGVGWIRQPSGKGLEWLASIFWNENKYYNPALMSRLTISRDTSKNLVFLTVASVDTADTGTYFCARITYPFFPMDYWGQGTSVTVSS(SEQ ID NO:2)
抗噻虫啉单克隆抗体C4C4轻链可变区序列为
CAGGCTGGTGTGACTCAGGAATCTACACTCACCACATCACCTGGTGAAACAGTCACACTCACTTGTCGCTCAAGTACTGGGACTGTTACAACTAGTAACTATGCCAACTGGGTCCAAGAAAAACCAGATCATTTATTCACTGGTCTAATAGGTGGTACCAACCACCGAGCTCCAGGTGTTCCTGCCAGATTCTCAGGCTCCCTGATTGGAGACAAGGCTGTCCTCACCATTACAGGGGCACAGACTGAGGATGAGGCAATGTATTTCTGTGCTCTGTGGTTCGGCAACCTTTGGGTGTTCGGTGGAGGAACCAAACTGACTGTCCTA(SEQ ID NO:3)
功能性轻链可变区全长为个327个碱基,结构域从第1位碱基开始,编码109个氨基酸,该功能性轻链V-GENE与鼠源IGLV1*01F的一致性为96.53%,J-GENE与鼠源IGLJ1*01F的一致性为100.00%。
以IMGT法定义结构域,具体结构域划分为:
结构域 | FR1 | CDR1 | FR2 | CDR2 | FR3 | CDR3 | FR4 |
碱基序列 | 1-75 | 76-102 | 103-153 | 154-162 | 163-270 | 271-297 | 298-327 |
抗噻虫啉单克隆抗体C4C4轻链可变区氨基酸序列
QAGVTQESTLTTSPGETVTLTCRSSTGTVTTSNYANWVQEKPDHLFTGLIGGTNHRAPGVPARFSGSLIGDKAVLTITGAQTEDEAMYFCALWFGNLWVFGGGTKLTVL(SEQ ID NO:4)
2)表达质粒的构建
在鉴定出正确的噻虫啉C4C4的重链和轻链可变区基因后,合成正确的基因序列。采用同源重组法分别将重链和轻链可变区基因连接到经过HindIII/EcoRI双酶切线性化的表达载体pCDNA3.4-Mouse-IgG1-CH和pCDNA3.4-Mouse-Cλ上。其中,pCDNA3.4-Mouse-IgG1-CH上面含有小鼠IgG1重链恒定区域基因,pCDNA3.4-Mouse-Cλ上面含有小鼠Lambda轻链恒定区域基因,故构建的重/轻链重组质粒上面分别包含了重链可变区基因和恒定区基因/轻链可变区基因和恒定区基因。将构建的重组质粒转化大肠杆菌TOP10感受态细胞、摇菌培养并测序。
3)重组完整抗体的表达
将测序正确的质粒对应的菌液继续大体积培养扩增,提取质粒,待用。复苏HEK293(F)细胞,120rpm,8%CO2,37℃悬浮培养3代。转染前,将细胞接种至新的培养瓶,接种密度为1.5×106个/mL,悬浮培养2h后,将重链质粒、轻链质粒和转染试剂按照一定的比例37℃静置孵育15min后,转染HEK293(F)细胞。转染后的细胞悬浮培养至活率低于70%后,4000rpm离心5min,收集上清培养液,采用Protein A亲和层析柱纯化细胞上清中重组完整抗体,纯化过程中液体流速均为1mL/min。纯化后的抗体用0.01M PBS溶液进行透析过夜,透析结束后,测定抗体浓度为3mg/mL,采用SDS-PAGE(图2)进行验证。
重组完整抗体的活性评价
抗噻虫啉重组完整抗体和抗噻虫啉天然小鼠腹水单抗用ELISA方法进行对比
将噻虫啉-OVA(混合酸酐法制备)作为包被原包被96孔板,然后用兔抗鼠IgG-HRP作为检测抗体,TMB作为反应底物,噻虫啉和其他新烟碱类农药标准品作为检测物,进行ELISA检测。结果(图3)如下:
a)检测范围
抗噻虫啉重组完整抗体用于ELISA法检测范围(IC20-IC80)为:0.27-2.01μg/L。
抗噻虫啉小鼠腹水单抗用于ELISA法检测范围(IC20-IC80)为:0.11-1.94μg/L。
b)灵敏度(IC50)
抗噻虫啉重组完整抗体IC50为:0.73μg/L,抗噻虫啉小鼠单克隆抗体IC50为:0.46μg/L,均比目前公开报道的噻虫啉抗体更为灵敏。
c)ELISA法特异性
本发明中通过检测与其他七种常见的新烟碱类杀虫剂的交叉反应来评价抗体的特异性。ELISA数据显示抗噻虫啉的鼠单抗和重组完整抗体与啶虫脒有30%左右的交叉反应率,与剩余的6种杀虫剂则没有交叉反应(CR<2%)。
因此,抗噻虫啉重组完整抗体和鼠源单克隆抗体对7种常见的新烟碱类农药具有相同的选择性,以及对噻虫啉表现出高灵敏识别作用。
上述具体实施方式用来解释说明本发明,而不是对本发明进行限制,在本发明的精神和权利要求的保护范围内,对本发明作出的任何修改和改变,都落入本发明的保护范围。
SEQUENCE LISTING
<110> 浙江大学
<120> 一种特异性抗噻虫啉抗体的可变区序列及其重组完整抗体
<130> 1
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 360
<212> DNA
<213> Mus musculus
<400> 1
caggttactc tgagagagtc tggccctggg atgttgcagc cctcccagac tctcagtctg 60
acctgttctt tctctggatt ttcaatgagc acttttgcta tgggtgtagg ctggattcgt 120
cagccttcag ggaagggact ggagtggctg gcaagtattt tttggaatga gaataaatat 180
tataatccag ccctgatgag ccggctcaca atctccaggg atacctccaa aaacctggtt 240
ttcctcacgg tcgccagtgt ggacactgca gatactggca catacttctg cgctcggata 300
acttacccct tctttcctat ggattactgg ggtcaaggaa cctcagtcac cgtctcctca 360
<210> 2
<211> 120
<212> PRT
<213> Mus musculus
<400> 2
Gln Val Thr Leu Arg Glu Ser Gly Pro Gly Met Leu Gln Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Met Ser Thr Phe
20 25 30
Ala Met Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
35 40 45
Trp Leu Ala Ser Ile Phe Trp Asn Glu Asn Lys Tyr Tyr Asn Pro Ala
50 55 60
Leu Met Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Asn Leu Val
65 70 75 80
Phe Leu Thr Val Ala Ser Val Asp Thr Ala Asp Thr Gly Thr Tyr Phe
85 90 95
Cys Ala Arg Ile Thr Tyr Pro Phe Phe Pro Met Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Ser Val Thr Val Ser Ser
115 120
<210> 3
<211> 327
<212> DNA
<213> Mus musculus
<400> 3
caggctggtg tgactcagga atctacactc accacatcac ctggtgaaac agtcacactc 60
acttgtcgct caagtactgg gactgttaca actagtaact atgccaactg ggtccaagaa 120
aaaccagatc atttattcac tggtctaata ggtggtacca accaccgagc tccaggtgtt 180
cctgccagat tctcaggctc cctgattgga gacaaggctg tcctcaccat tacaggggca 240
cagactgagg atgaggcaat gtatttctgt gctctgtggt tcggcaacct ttgggtgttc 300
ggtggaggaa ccaaactgac tgtccta 327
<210> 4
<211> 109
<212> PRT
<213> Mus musculus
<400> 4
Gln Ala Gly Val Thr Gln Glu Ser Thr Leu Thr Thr Ser Pro Gly Glu
1 5 10 15
Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Thr Val Thr Thr Ser
20 25 30
Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Asp His Leu Phe Thr Gly
35 40 45
Leu Ile Gly Gly Thr Asn His Arg Ala Pro Gly Val Pro Ala Arg Phe
50 55 60
Ser Gly Ser Leu Ile Gly Asp Lys Ala Val Leu Thr Ile Thr Gly Ala
65 70 75 80
Gln Thr Glu Asp Glu Ala Met Tyr Phe Cys Ala Leu Trp Phe Gly Asn
85 90 95
Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
Claims (4)
1.一种抗噻虫啉重组完整抗体,包括重链恒定区、重链可变区、轻链恒定区和轻链可变区,其特征在于:所述重链可变区的氨基酸序列如SEQ ID NO:2所示;所述轻链可变区的氨基酸序列如SEQ ID NO:4所示。
2.根据权利要求1所述的抗噻虫啉重组完整抗体,其特征在于:所述重链可变区编码基因的核苷酸序列如SEQ ID NO:1所示。
3.根据权利要求1所述的抗噻虫啉重组完整抗体,其特征在于:所述轻链可变区编码基因的核苷酸序列如SEQ ID NO:3所示。
4.一种抗体表达质粒,其特征在于:含有如权利要求1-2中任一项所述的重链可变区和小鼠重链IgG1恒定区的核苷酸序列,可以表达抗噻虫啉重组完整抗体的重链蛋白;且,含有如权利要求1、权利要求3中任一项所述的轻链可变区和小鼠轻链Lambda恒定区的核苷酸序列,可以表达抗噻虫啉重组完整抗体的轻链蛋白。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010736700.2A CN112111010B (zh) | 2020-07-28 | 2020-07-28 | 一种特异性抗噻虫啉抗体的可变区序列及其重组完整抗体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010736700.2A CN112111010B (zh) | 2020-07-28 | 2020-07-28 | 一种特异性抗噻虫啉抗体的可变区序列及其重组完整抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112111010A CN112111010A (zh) | 2020-12-22 |
CN112111010B true CN112111010B (zh) | 2022-04-19 |
Family
ID=73799109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010736700.2A Active CN112111010B (zh) | 2020-07-28 | 2020-07-28 | 一种特异性抗噻虫啉抗体的可变区序列及其重组完整抗体 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112111010B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113563472B (zh) * | 2021-07-16 | 2023-05-23 | 浙江大学 | 一种特异性抗百菌清抗体的可变区序列及其重组全长IgG抗体 |
CN114106189B (zh) * | 2021-11-23 | 2023-07-28 | 福州大学 | 一种抗四溴双酚a-双(2-羟乙基)醚单链抗体的氨基酸序列及其表达载体 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104974256A (zh) * | 2015-04-10 | 2015-10-14 | 南京农业大学 | 一种抗噻虫啉单克隆抗体及其用途 |
CN104974255A (zh) * | 2014-04-04 | 2015-10-14 | 浙江省海洋开发研究院 | 噻虫啉单克隆抗体的制备及elisa检测方法 |
CN105400742A (zh) * | 2015-11-25 | 2016-03-16 | 浙江大学 | 杂交瘤细胞株imi-g12及其产生的新烟碱类农药通用单克隆抗体和应用 |
CN105754955A (zh) * | 2016-05-17 | 2016-07-13 | 江南大学 | 一株噻虫啉、啶虫脒单克隆抗体杂交瘤细胞株gw及其应用 |
CN109991419A (zh) * | 2019-03-18 | 2019-07-09 | 浙江大学 | 基于spr技术的烟碱类杀虫剂噻虫啉残留检测方法 |
-
2020
- 2020-07-28 CN CN202010736700.2A patent/CN112111010B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104974255A (zh) * | 2014-04-04 | 2015-10-14 | 浙江省海洋开发研究院 | 噻虫啉单克隆抗体的制备及elisa检测方法 |
CN104974256A (zh) * | 2015-04-10 | 2015-10-14 | 南京农业大学 | 一种抗噻虫啉单克隆抗体及其用途 |
CN105400742A (zh) * | 2015-11-25 | 2016-03-16 | 浙江大学 | 杂交瘤细胞株imi-g12及其产生的新烟碱类农药通用单克隆抗体和应用 |
CN105754955A (zh) * | 2016-05-17 | 2016-07-13 | 江南大学 | 一株噻虫啉、啶虫脒单克隆抗体杂交瘤细胞株gw及其应用 |
CN109991419A (zh) * | 2019-03-18 | 2019-07-09 | 浙江大学 | 基于spr技术的烟碱类杀虫剂噻虫啉残留检测方法 |
Non-Patent Citations (4)
Title |
---|
A fluorescence polarization immunoassay for detection of thiacloprid in environmental and agricultural samples;Yuan Din等;《RSC Adv.》;20191231;第9卷;第36825-36830页 * |
Development of an enzyme-linked immunosorbent assay for thiacloprid in soil and agro-products with phage-displayed peptide;Wei Yin等;《Analytical Biochemistry》;20150420;第481卷;第27-32页 * |
Development of an immunochromatographic strip for detection of acetamiprid in cucumber and apple samples;Liqiang Liu等;《FOOD AND AGRICULTURAL IMMUNOLOGY》;20170405;第28卷(第5期);第767-778页 * |
噻虫啉单克隆抗体的制备及其免疫分析方法研究;冯璐;《中国优秀硕士学位论文全文数据库 工程科技I辑》;20190715;第B016-532页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112111010A (zh) | 2020-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112111011B (zh) | 一种特异性抗噻虫嗪抗体的可变区序列及其重组全长抗体 | |
CN112111009B (zh) | 一种特异性抗吡唑醚菌酯抗体的可变区序列及其重组全长抗体 | |
CN112111010B (zh) | 一种特异性抗噻虫啉抗体的可变区序列及其重组完整抗体 | |
CN113563472B (zh) | 一种特异性抗百菌清抗体的可变区序列及其重组全长IgG抗体 | |
Xu et al. | Construction of an immunized rabbit phage display library for selecting high activity against Bacillus thuringiensis Cry1F toxin single-chain antibodies | |
CN114057870A (zh) | 用于新型冠状病毒Delta突变株检测的标记抗体及其应用 | |
CN112194725B (zh) | 一种特异性抗噻虫胺抗体的可变区序列及其重组完整抗体的制备与应用 | |
CN112010969B (zh) | 一种高亲和力增强绿色荧光蛋白纳米抗体及其编码基因的筛选方法 | |
JP7117088B2 (ja) | 抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法 | |
CN116535510B (zh) | 一种抗人pla2r的抗体、试剂盒及其应用 | |
Chusri et al. | Production and characterization of a monoclonal antibody against enrofloxacin | |
US20220033524A1 (en) | Variable region sequence of broad-spectrum antibody against clothianidin and dinotefuran and preparation of intact recombinant antibody thereof | |
Bogen et al. | Humanization of chicken-derived antibodies by yeast surface display | |
CN111484553A (zh) | 一种靶向补体蛋白C5的pH依赖性抗体的筛选方法 | |
CN111471109A (zh) | 一种抗成纤维细胞生长因子受体4单克隆抗体及其制备方法和用途 | |
CN112409487B (zh) | 抗可溶性转铁蛋白受体抗体及其应用 | |
US20210380719A1 (en) | Rabbit antibodies to human immunoglobulins g | |
CN110872354A (zh) | 哺乳动物细胞重组抗人tk1的鸡源的单克隆抗体、单链抗体及其制备方法和应用 | |
CN113004405B (zh) | 一种包含NT-proBNP抗原结合结构域的分离的结合蛋白 | |
CN104762268B (zh) | 一种高亲和力抗重金属镉单克隆抗体及其应用 | |
CN114133453B (zh) | 一种抗氨基甲酸酯类农药的宽谱单克隆抗体及其可变区序列 | |
CN117164718A (zh) | 抗毒死蜱的高亲和、特异性单克隆抗体及其重组全长抗体表达质粒 | |
CN117264072B (zh) | 一种抗sn38单抗及其应用 | |
CN116143929B (zh) | 抗重组人凝血因子VIIa-Fc融合蛋白的抗体及其应用 | |
CN118440194A (zh) | 用于检测鼠白介素-2的抗体、抗体对及检测试剂或试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |